Current Challenges of Preventive Vaccination Against Rabies
https://doi.org/10.30895/2221-996X-2019-19-1-10-16
Abstract
The urgency of the rabies problem for all mankind and the search for new ways of eradicating the disease entailed the creation of a new global initiative for rabies elimination ‒ «United Against Rabies» which sets a highly ambitious goal of achieving zero rabies human deaths by 2030. The many years of international experience in elimination of street dogs, which account for 99 % of rabies cases, did not produce the desired results, therefore the focus was shifted to mass vaccination of dogs (minimum 70 % of dog population). The rabies problem is complex and global, it requires efforts from all the parties involved as well as hefty investment. The paper presents the results of a continuous long-term analysis of the rabies situation in Russia and across the world, as well as analysis of the current state of vaccination against rabies which plays an important, if not crucial, role in prevention of rabies in humans who got bitten by infected animals. The paper formulates the main currently existing ways of solving the rabies problem, namely: mass vaccination of dogs; improvement of dosing schedules and administration routes of medicines against rabies; analysis of immunity development mechanisms in immunocompromised patients; progressive implementation of vaccination of people who got bitten by infected animals, and alternative administration routes; development of an express method of the neutralising antibody titer determination; raising public awareness about disease hazards.
Keywords
rabies,
pre- and post-exposure vaccination,
rabies vaccine,
rabies immunoglobulin,
immunisation methods and schemes
Funding: The study reported in this publication was carried out as part of a publicly funded research project No. 056-00154-19-00 and was supported by the Scientific Centre for Expert Evaluation of Medicinal Products (R&D public accounting No. АААА-А18-118021590046-9)
About the Authors
A. A. Movsesyants
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Doctor of Medical Sciences, Professor, Head of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality of the Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Doctor of Medical Sciences, Professor, Head of the Testing Centre for Evaluation of Medicinal Immunobiological Products’ Quality of the Scientific Centre for Expert Evaluation of Medicinal Products
Yu. V. Olefir
Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Doctor of Medical Sciences, Senior Research Associate, General Director of the Scientific Centre for Expert Evaluation of Medicinal Products
Russian Federation
Doctor of Medical Sciences, Senior Research Associate, General Director of the Scientific Centre for Expert Evaluation of Medicinal Products
References
1. Kopel E, Oren G, Sidi Y, David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis. 2012;18(9):1493–5. https://doi.org/10.3201/eid1809.111833
2. Bakulov IA, Kotlyarov VM. World epizootic situation on diseases of wild animals. In: Biological and environmental problems of infectious diseases of wild animals and their role in the pathology of farm animals and people: Materials of the international scientific conference. Pokrov, April 16–18, 2002. Pokrov; 2002. P. 5–9 (In Russ.)
3. Movsesyants AA, Vedernikov VA. Rabies cases per country and administrative units, 4th quartes 2011 in Russian Federation. WHO Rabies Bulletin Europe. 2012;35(4).
4. Tordo N, Bahloul C, Jacob Y, Jallet C, Perrin P, Badrane H. Rabies: epidemiological tendencies and control tools. Dev Biol (Basel). 2006;125:3–13.
5. Elmore SA, Chipman RB, Slate D, Huyvaert KP, VerCauteren KC, Gilbert AT. Management and modeling approaches for controlling raccoon rabies: The road to elimination. PloS Negl Trop Dis. 2017;11(3):e0005249. https://doi.org/10.1371/journal.pntd.0005249
6. Selimov MA. Rabies. Moscow: Meditsina; 1978 (In Russ.)
7. Movsesyants AA, Bektimirov TA. Hydrophobia in humans treated with specific immune drugs. Veterinarnaya patologiya = Veterinary Pathology. 2002;(1):40 (In. Russ.)
8. Ambrozaitis A, Laiškonis A, Balčiuniene L, Banzhoff A, Malerczyk C. Rabies post-exposure prophylaxis vaccination with purified chick embryo cell vaccine (PCECV) and purified vero cell rabies vaccine (PVRV) in a four-site intradermal schedule (4-0-2-0-1-1): An immunogenic, cost-effective and practical regimen. Vaccine. 2006;24(19):4116–21. https://doi.org/10.1016/j.vaccine.2006.02.036
9. Brown D, Featherstone JJ, Fooks AR, Gettner S, Lloyd E, Schweiger M. Intradermal pre-exposure rabies vaccine elicits long lasting immunity. Vaccine. 2008;26(31):3909–12. https://doi.org/10.1016/j.vaccine.2008.04.081
10. Kopel E, Oren G, Sidi Y, David D. Inadequate antibody response to rabies vaccine in immunocompromised patient. Emerg Infect Dis. 2012;18(9):1493–5. https://doi.org/10.3201/eid1809.111833
11. Jackson AC, Warrell MJ, Rupprecht CE, Ertl HC, Dietzschold B, O'Reilly M, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60–3. https://doi.org/10.1086/344905
12. Movsesyants AA, Vedernikov VA. Rabies cases per country and administrative units, 4th quartes 2011 in Russian Federation. WHO Rabies Bulletin Europe. 2012;35(4).
13. Movsesyants AA, Kravchenko AT. Prevention and treatment of rabies: achievements and challenges. Zhurnal mikrobiologii, epidemiologii i immunobiologii=Journal of Microbiology, Epidemiology and Immunobiology. 1989;(8):97–104 (In Russ.)
14. Elmore SA, Chipman RB, Slate D, Huyvaert KP, VerCauteren KC, Gilbert AT. Management and modeling approaches for controlling raccoon rabies: The road to elimination. PloS Negl Trop Dis. 2017;11(3):e0005249. https://doi.org/10.1371/journal.pntd.0005249
15. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009;27(51):7141–8. https://doi.org/10.1016/j.vaccine.2009.09.029
16. Movsesyants AA, Bektimirov TA. Hydrophobia in humans treated with specific immune drugs. Veterinarnaya patologiya = Veterinary Pathology. 2002;(1):40 (In. Russ.)
17. Brown D, Featherstone JJ, Fooks AR, Gettner S, Lloyd E, Schweiger M. Intradermal pre-exposure rabies vaccine elicits long lasting immunity. Vaccine. 2008;26(31):3909–12. https://doi.org/10.1016/j.vaccine.2008.04.081
18. Jackson AC, Warrell MJ, Rupprecht CE, Ertl HC, Dietzschold B, O'Reilly M, et al. Management of rabies in humans. Clin Infect Dis. 2003;36(1):60–3. https://doi.org/10.1086/344905
19. Movsesyants AA, Kravchenko AT. Prevention and treatment of rabies: achievements and challenges. Zhurnal mikrobiologii, epidemiologii i immunobiologii=Journal of Microbiology, Epidemiology and Immunobiology. 1989;(8):97–104 (In Russ.)
20. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Evidence for a 4-dose vaccine schedule for human rabies post-exposure prophylaxis in previously non-vaccinated individuals. Vaccine. 2009;27(51):7141–8. https://doi.org/10.1016/j.vaccine.2009.09.029
Review
For citations:
Movsesyants A.A., Olefir Yu.V. Current Challenges of Preventive Vaccination Against Rabies. BIOpreparations. Prevention, Diagnosis, Treatment. 2019;19(1):10-16. (In Russ.) https://doi.org/10.30895/2221-996X-2019-19-1-10-16
Views:
2039
Email this article 